MedTrace Logo

Augmented Interoceptive Exposure Training in Anorexia Nervosa

NCT03019081 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-10-05

No results posted yet for this study

Summary

The researchers propose to utilize a pharmacological approach involving infusions of the sympathomimetic agent isoproterenol to repeatedly trigger cardiorespiratory sensations and anxiety during meal anticipation, to facilitate the development of tolerance or a reduction of the anxiety/fear response in individuals with anorexia nervosa. The investigators aim to conduct a proof of principle study to assess for evidence of initial efficacy of this new treatment approach. As a comparator condition, the researchers propose using repeated administration of saline infusions.

Conditions

  • Anorexia Nervosa

Interventions

DRUG

Isoproterenol

The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.

OTHER

placebo

placebo

Sponsors & Collaborators

  • Brain & Behavior Research Foundation

    collaborator OTHER

  • Laureate Institute for Brain Research, Inc.

    lead OTHER

Principal Investigators

  • Sahib S Khalsa, MD, PhD · Laureate Institute for Brain Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2021-08-31
Completion
2024-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03019081 on ClinicalTrials.gov